image dons

je fais un don

ATLANTIC

Étude Internationale, multicentrique, randomisée visant à évaluer l’impact de l’utilisation d’une dose de charge de Ticagrelor en pré-hospitalier versus en intra-hospitalier dans le traitement de l’infarctus du myocarde aigu avec sus décalage du segment ST et traité par angioplastie primaire

Terminée

logo étude

objectif

Étude Internationale, multicentrique, randomisée visant à évaluer l’impact de l’utilisation d’une dose de charge de Ticagrelor en pré-hospitalier versus en intra-hospitalier dans le traitement de l’infarctus du myocarde aigu avec sus décalage du segment ST et traité par angioplastie primaire.

date de réalisation

2011

nombre de patients

1858

nombre de centres participants

112 centres dans 13 pays

type de financement

Privé (AstraZeneca)

Référence

NCT01347580

A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) (ATLANTIC)

Study Description

The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention (PCI) and optimizing the outcome for the patient.
The study will assess the efficacy and safety of pre-hospital compared to in-hospital administration of ticagrelor in co-administration with aspirin, on restoring the blood flow in the occluded heart artery and improving the myocardial perfusion in patients suffering from myocardial infarction and planned to have a PCI. Patients can be randomised in either one of the 2 arms :

  • re-hospital ticagrelor arm: Patients will receive a loading dose of 180 mg ticagrelor for the pre-hospital administration and placebo for in-hospital administration.
  • or In-hospital ticagrelor arm: Patients will receive a placebo for pre-hospital administration and 180 mg ticagrelor loading dose for in-hospital administration.

Patients are initially managed by ambulance physician/personnel in pre hospital settings. They are then transferred into a Catheterization room to undergo a PCI. After the administration of the loading dose of ticagrelor (double blind), patients will continue on ticagrelor 90 mg bid and be followed in study for 30 days post randomisation.

source clinicaltrials.gov

Publications

  • Prehospital ticagrelor in ST-segment elevation myocardial infarction
    Gilles Montalescot, Arnoud W van 't Hof, Frédéric Lapostolle, Johanne Silvain, Jens Flensted Lassen, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Uwe Zeymer, Olivier Stibbe, Patrick Ecollan, Wim M J M Heutz, Eva Swahn, Jean-Philippe Collet, Frank F Willems, Caroline Baradat, Muriel Licour, Anne Tsatsaris, Eric Vicaut, Christian W Hamm, ATLANTIC Investigators
    Publié dans The New England Journal of Medecine
  • Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction : ATLANTIC-Morphine
    Frédéric Lapostolle, Arnoud W Van't Hof, Christian W Hamm, Olivier Stibbe, Patrick Ecollan, Jean-Philippe Collet, Johanne Silvain, Jens Flensted Lassen, Wim M J M Heutz, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Jur Ten Berg, Uwe Zeymer, Muriel Licour, Anne Tsatsaris, Gilles Montalescot, ATLANTIC Investigators
    Publié dans American Journal of Cardiovascular Drugs
  • Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty : A sub-analysis of the ATLANTIC trial
    Enrico Fabris, Arnoud Van't Hof, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Shaun G Goodman, Jurriën M Ten Berg, Leonardo Bolognese, Angel Cequier, Mohamed Chettibi, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Uwe Zeymer, Warren J Cantor, Mathieu Kerneis, Abdourahmane Diallo, Eric Vicaut, Gilles Montalescot, ATLANTIC investigators
    Publié dans Catheterization & Cardiovascular Interventions
  • Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction : Insights from the ATLANTIC study
    Akshay Bagai, Shaun G Goodman, Warren J Cantor, Eric Vicaut, Leonardo Bolognese, Angel Cequier, Mohamed Chettibi, Christopher J Hammett, Kurt Huber, Magnus Janzon, Frédéric Lapostolle, Jens Flensted Lassen, Béla Merkely, Robert F Storey, Jurriën M Ten Berg, Uwe Zeymer, Abdourahmane Diallo, Christian W Hamm, Anne Tsatsaris, Jad El Khoury, Arnoud W Van't Hof, Gilles Montalescot
    Publié dans American Heart Journal
  • Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction : Findings from the ATLANTIC trial
    Sinem Kilic, Enrico Fabris, Arnoud W J Van't Hof, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Anne Tsatsaris, Abdourahmane Diallo, Eric Vicaut, Gilles Montalescot, ATLANTIC Investigators
    Publié dans American Heart Journal
  • Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population
    Guillaume Cayla, Frédéric Lapostolle, Patrick Ecollan, Olivier Stibbe, Jean Francois Benezet, Patrick Henry, Christopher J Hammett, Jens Flensted Lassen, Robert F Storey, Jur M Ten Berg, Christian W Hamm, Arnoud W Van't Hof, Gilles Montalescot, ACTION study group
    Publié dans International Journal of Cardiology
  • P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study
    Johanne Silvain, Robert F Storey, Guillaume Cayla, Jean-Baptiste Esteve, Jean-Guillaume Dillinger, Hélène Rousseau, Anne Tsatsaris, Caroline Baradat, Néjoua Salhi, Christian W Hamm, Frédéric Lapostolle, Jens Flensted Lassen, Jean-Philippe Collet, Jurriën M Ten Berg, Arnoud W Van't Hof, Gilles Montalescot
    Publié dans Thrombosis and Haemostasis
  • Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H24 Analysis
    Gilles Montalescot, Arnoud W van 't Hof, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Jean-Philippe Collet, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Frédéric Lapostolle, Jens Flensted Lassen, Muriel Licour, Béla Merkely, Néjoua Salhi, Johanne Silvain, Robert F Storey, Jurriën M Ten Berg, Anne Tsatsaris, Uwe Zeymer, Eric Vicaut, Christian W Hamm, ATLANTIC Investigators
    Publié dans JACC: Cardiovascular Interventions
  • Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction : rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study
    Gilles Montalescot, Jens Flensted Lassen, Christian W Hamm, Frédéric Lapostolle, Johanne Silvain, Jurriën M ten Berg, Warren J Cantor, Shaun G Goodman, Muriel Licour, Anne Tsatsaris, Arnoud W van't Hof
    Publié dans American Heart Journal

Présentations

  • ESC2017 - Poster 'Thrombus aspiration ATLANTIC Trial'
    powerpoint pdf
  • ESC2017 - Poster 'ST-segment resolution ATLANTIC Trial'
    powerpoint pdf
  • ESC2016 - Poster 'ST-resolution ATLANTIC Study'
    pdf

Autres études

+

ARAMIS

En cours


Évaluation de l’Anakinra versus placebo dans le traitement de la myocardite aigüe et évaluation de la poursuite du traitement de référence par IEC chez patients sans dysfonction ventriculaire.
+

AFIJI

En cours


Registre visant à évaluer l’impact de la génétique sur l’apparition des maladies coronaires chez le sujet jeune et la pharmacogénétique du clopidogrel et son impact sur le pronostic des patients ayant...
+

AFLOAT

À venir


Évaluer l'efficacité de la flécaïnide par rapport au traitement standard dans la prévention de la FA au cours des 3 mois après une procédure de fermeture de FOP.